MedTrace Logo

CBD Oil for Reducing Emotional Impact of COVID-19

NCT04603781 · Status: SUSPENDED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-11-22

No results posted yet for this study

Summary

Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg. of broad- spectrum CBD Oil, or Placebo oil among adults presenting with COVID-19 -induced stress reactions including one or more of the following: anxiety, depression, anger, substance use, or sleep disturbance.

Conditions

  • Anxiety Depression
  • Alcohol Abuse
  • Substance Abuse
  • Anger
  • Sleep Disturbance
  • Stress Reaction

Interventions

DIETARY_SUPPLEMENT

CBD Isolate

300 mg. daily dose of CBD Isolate Oil

DIETARY_SUPPLEMENT

Full Spectrum CBD Oil

300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant

DIETARY_SUPPLEMENT

Broad-Spectrum CBD Oil

300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant

DIETARY_SUPPLEMENT

Placebo Oil

MCT Oil with mint flavoring

Sponsors & Collaborators

  • Way West Wellness

    collaborator UNKNOWN

  • SunFlora.Inc

    collaborator UNKNOWN

  • University of Texas at Austin

    lead OTHER

Principal Investigators

  • Michael J Telch, Ph.D. · University of Texas at Austin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-04
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603781 on ClinicalTrials.gov